IMEDEX: Interactive Case: Ovarian Cancer: Front-Line Therapy in Patient with Inadequate Debulking Surgery

Note:  registration required (free), discusses Japanese trial with weekly Taxol and increased overall survival, GOG 262 ((see arms 1 & 2)  etc...

Interactive Case: Ovarian Cancer: Front-Line Therapy in Patient with Inadequate Debulking Surgery VIEW ACTIVITY Overview: Dr Bradley Monk very eloquently describes a case of newly diagnosed advanced ovarian cancer and reinforces the importance of debulking surgery and combination chemotherapy. Various therapeutic options and recent clinical trial data are discussed. Topics: • Small and large volume residual disease and treatment decision making • Standards and clinical trials • Role of antiangiogenic agents in ovarian cancer management

(NCCN) Updated Ovarian Cancer Guidelines Offer a New Treatment Choice

Note: this refers to the Japanese study published 2010 of weekly Taxol - search blog for the original study and additional commentaries


March 14, 2011 — The updated 2011 National Comprehensive Cancer Network (NCCN) Ovarian Cancer Guidelines have added a new treatment option — dose-dense paclitaxel — for the first-line treatment of stage II, III, or IV epithelial ovarian cancer.

The category 1 recommendation comes from data from the Japanese Gynecologic Oncology Group, said panel chair Robert J. Morgan, MD, professor of medicine at the City of Hope Comprehensive Cancer Center in Duarte, California, here at the NCCN 16th Annual Conference.

In a phase 3 open-label randomized controlled trial published in the Lancet (2009; 374:1331-1338), Noriyuki Katsumata and colleagues reported that dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer resulted in a significant survival advantage. The study concluded that paclitaxel and carboplatin given every 3 weeks is standard treatment for advanced ovarian carcinoma.

"This was an important addition," Dr. Morgan told Medscape Medical News........"